Open Nav

Navigating Checkpoint Inhibitors’ Clinical Results: Lessons for CEOs and Investors

  • Kenneth LaMontagne, The Leukemia & Lymphoma Society,
  • Karin Jooss, Gritstone Oncology,
  • Eugene P. Kennedy, NewLink Genetics,
  • Angèle Maki, Merck & Co,
  • Thomas W. Dubensky Jr., Tempest Therapeutics

In the past three years, the number of U.S. clinical trials testing checkpoint inhibitors in combination immunotherapies has quintupled to nearly 1,300 trials. Two types of therapeutic approaches have tried to demonstrate their value to magnify the successful performance of PD-1/PD-L1 inhibitors as combination partners: IDO inhibitors and oncolytic viruses. The former partner therapy has delivered initial disappointments in the past year, while combining oncolytic viruses with checkpoint inhibitors has seen promising clinical results. This panel reviews the current landscape of checkpoint inhibitor development, highlighting lessons that can be gained from recent achievements and setbacks in combination immunotherapies.

Moderator: Kenneth LaMontagne, PhD, MBA, Vice President, Research TAP (Therapy Acceleration Program), The Leukemia & Lymphoma Society

  • Date:Wednesday, October 17
  • Time:8:30 AM - 9:40 AM
  • Session Type:Educational Session
Kenneth LaMontagne
The Leukemia & Lymphoma Society
Karin Jooss
Gritstone Oncology
Eugene P. Kennedy
NewLink Genetics
Angèle Maki
Merck & Co
Thomas W. Dubensky Jr.
Tempest Therapeutics